ONC - BeiGene, Ltd.

312.31
-5.760   -1.844%

Share volume: 189,085
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$318.07
-5.76
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
51%
Profitability 45%
Dept financing 28%
Liquidity 75%
Performance 58%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.57%
1 Month
13.68%
3 Months
-7.82%
6 Months
-0.39%
1 Year
23.56%
2 Year
20.58%
Key data
Stock price
$312.31
P/E Ratio 
117.17
DAY RANGE
$311.58 - $317.42
EPS 
$0.20
52 WEEK RANGE
$218.31 - $385.22
52 WEEK CHANGE
$25.36
MARKET CAP 
33.619 B
YIELD 
N/A
SHARES OUTSTANDING 
222.510 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$225,702
AVERAGE 30 VOLUME 
$211,206
Company detail
CEO: John V. Oyler
Region: US
Website: beigene.com
Employees: 9,000
IPO year: 2016
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)

Recent news